Hantaviruses: Immunology, treatment, and prevention

Viral Immunology

Volumn 17, Issue 4, 2004, Pages 481-497

  Maes, Piet ^a   Clement, Jan ^a   Gavrilovskaya, Irina ^b   Van Ranst, Marc ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASTRAGALUS MEMBRANACEUS EXTRACT; BETA INTERFERON; CYTOPLASM PROTEIN; GAMMA INTERFERON; GUM TRAGACANTH; HANTAVAX; HANTAVIRUS VACCINE; MYXOVIRUS RESISTANCE PROTEIN A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; BUNYAVIRUS; CRUSH SYNDROME; CYTOPATHOLOGY; DISEASE ASSOCIATION; HANTAVIRUS; HEMORRHAGIC FEVER; IMMUNOPATHOLOGY; INFECTION PREVENTION; LABORATORY DIAGNOSIS; LUNG INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; SYNDROME DELINEATION; VACCINE PRODUCTION; VASCULAR DISEASE; VIRUS IMMUNITY;

ASTRAGALUS MEMBRANACEUS; HANTAVIRUS; MYXOVIRUS; ORTHOBUNYAVIRUS; RNA VIRUSES; RODENTIA;

EID: 11144236244     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2004.17.481     Document Type: Review

References (163)

1. Acha, P.N. 1967. Rabies vaccine prepared in suckling mouse brain. Bull. Off. Int. Epizoot. 67:439-442.
2. Akhmatova, N.K., R.S. Yusupova, S.F. Khaiboullina, et al. 2003. Lymphocyte apoptosis during hemorrhagic fever with renal syndrome. Russ. J. Immunol. 8:37-46.
3. Alexeyev, O.A., C. Ahlm, J. Billheden, et al. 1994. Elevated levels of total and Puumala virus-specific immunoglobulin E in the Scandinavian type of hemorrhagic fever with renal syndrome. Clin. Diagn. Lab. Immunol. 1:269-272.
4. Alexeyev, O.A., M. Linderholm, F. Elgh, et al. 1997. Increased plasma levels of soluble CD23 in hemorrhagic fever with renal syndrome. Relation to virus-specific IgE. Clin. Exp. Immunol. 109:351-355.
5. Araki, K., K. Yoshimatsu, M. Ogino, et al. 2001. Truncated hantavirus nucleocapsid proteins for serotyping Hantaan, Seoul, and Dobrava hantavirus infections. J. Clin. Microbiol. 39:2397-404.
6. Arikawa, J., A.L. Schmaljohn, J.M. Dalrymple, et al. 1989. Characterization of Hantaan virus envelope glycoproteins antigenic determinants defined by monoclonal antibodies. J. Gen. Virol. 70:615-624.
7. Avsic-Zupanc, T., A. Toney, K. Anderson, et al. 1995. Genetic and antigenic properties of Dobrava virus: a unique member of the Hantavirus genus, family Bunyaviridae. J. Gen. Virol. 76:2801-2808.
8. Avsic-Zupanc, T., S.Y. Xiao, R. Stojanovic, et al. 1999. Characterization of Dobrava virus: a Hantavirus from Slovenia, Yugoslavia. J. Med. Virol. 38:132-137.
9. Bharadwaj, M., C.R. Lyons, I.A. Wortman, et al. 1999. Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune response in BALBc mice. Vaccine. 17:2836-2843.
10. Borish, L., J. J. Mascali, L.J. Rosenwasser. 1991. IgE-dependent cytokine production by human peripheral blood mononuclear phagocytes. J. Immunol. 146:63-67.
11. Bostik, P., J. Winter, T.G. Ksiazek, et al. 2000. Sin Nombre virus (SNV) Ig isotype antibody response during acute and convalescent phases of hantavirus pulmonary syndrome. Emerg. Infect. Dis. 6:184-187.
12. Brandtzaeg, P. 2003. Role of secretory antibodies in the defense against infections. Int. J. Med. Microbiol. 293:3-15.
13. Caly, W.R., E. Strauss, F.J. Carrilho, et al. 2003. Different degrees of malnutrition and immunological alterations to the aetiology of cirrhosis: a prospective and sequential study. Nutr. J. 2:10.
14. Cebalo, L., T. Dusek, I. Kuzman, et al. 2003. Grading the severity of disease in patients with Puumala or Dobrava virus infections from 1995 to 2000 in Croatia. Acta Med. Croatica. 57:355-359.
15. Chapman, L.E., G.J. Mertz, C.J. Peters, et al. 1999. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir. Ther. 4:211-219.
16. Cho, H.W., C.R. Howard. 1999. Antibody response in humans to an inactivated hantavirus vaccine (Hantavax). Vaccine. 17:2569-2575.
17. Cho, H.W., C.R. Howard, H.W. Lee. 2002. Review of an inactivated vaccine against hantaviruses. Intervirology. 45:328-333.
18. Choi, Y., C.J. Ahn, K.M. Seong, et al. 2003. Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells. Vaccine. 21:1867-1873.
19. Chu, Y.K., C. Rossi, J.W. Leduc, et al. 1994. Serological relationships among viruses in the Hantavirus genus, family Bunyaviridae. Virology. 198:196-204.
20. Chu, Y.K., G.B. Jennings, C.S. Schmaljohn. 1995. A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul virus but not Puumala virus. J. Virol. 69:6417-6423.
21. Clement, J., P. Colson, P. McKenna. 1994. Hantavirus pulmonary syndrome in New England and Europe. N. Engl. J. Med. 331:545-546.
22. Clement, J., P. McKenna, J. Groen, et al. 1995. Epidemiology and laboratory diagnosis of hantavirus (HTV) infections. Acta Clin. Belg. 50:9-19.
23. Clement, J., P. McKenna, G. van der Groen, et al. 1998. Hantaviruses. In: Zoonoses. Biology, Clinical Practice and Public Health Control. S.R. Palmer, E.J.L. Soulsby. D.I.H. Simpson. Oxford University Press, Oxford, New-York, Tokyo. 331-351.
24. Clement, J.P. 2003. Hantavirus. Antiviral Res. 57:121-127.
25. Cosgriff, T.M. 1991. Mechanisms of disease in hantavirus infection: Pathophysiology of hemorrhagic fever with renal syndrome. Rev. Infect. Dis. 13:97-107.
26. Custer, D.M., E. Thompson, C.S. Schmaljohn, et al. 2003. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J. Virol. 77:9894-9905.
27. Dargeviciute, A., K. Brus Sjölander, K. Sasnauskas, et al. 2002. Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model. Vaccine. 20:3523-3531.
28. de Carvalho Nicacio, C., M. Sallberg, C. Hultgren, et al. 2001. T-helper and humoral responses to Puumala hantavirus nucleocapsid protein: identification of T-helper epitopes in a mouse model. J. Gen. Virol. 82:129-138.
29. de Carvalho Nicacio, C., M. Gonzalez Della Valle, P. Padula, et al. 2002. Cross-Protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. J. Virol. 76:6669-6677.
30. Demanet, C., A. Mulder, V. Deneys, et al. 2004. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 103:3122-3130.
31. Duenas-Carrera, S. 2004. DNA vaccination against hepatitis C. Curr. Opin. Mol. Ther. 6:146-150.
32. Elgh, F., A. Lundkvist, O.A. Alexeyev, et al. 1997. Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes. J. Clin Microbiol. 35:1122-1130.
33. + cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology. 238:380-390.
34. Farr, R.W. 1994. Hantavirus pulmonary syndrome. W. V. Med. J. 90:422-425.
35. Frese, M., G. Kochs, H. Feldmann, et al. 1996. Inhibition of bunyaviruses, phleboviruses, and hantaviruses by human MxA protein. J. Virol. 70:915-923.
36. Garin, D., C. Peyrefitte, J.M. Crance, et al. 2001. Highly sensitive Taqman PCR detection of Puumala hantavirus. Microbes Infect. 3:739-745.
37. Gavrilovskaya, I.N., M. Shepley, R. Shaw, et al. 1998. Beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc. Natl. Acad. Sci. USA. 95:7074-7079.
38. Geimonen, E., S. Neff, T. Raymond, et al. 2002. Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proc. Natl. Acad. Sci. USA. 99:13837-13842.
39. Geldmacher, A., M. Schmaler, D.H. Krüger, et al. 2004. Yeast-expressed hantavirus Dobrava nucleocapsid protein induces a strong, long-lasting, and highly cross-reactive immune response in mice. Viral Immunol. 17:115-122.
40. Giri, M., K.F. Ugen, D.B. Weiner. 2004. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin. Microbiol. Rev. 17:370-389.
41. Glas, W.G., H.F. Rosenberg, P.M. Murphy. 2003. Chemokine regulation of inflammation during acute viral infection. Curr. Opin. Allergy Clin. Immunol. 3:467-473.
42. Gött, P., L. Zöller, G. Darai, et al. 1997. A major antigenic domain of hantaviruses is located on the amino-proximal site of the viral nucleocapsid protein. Virus Genes. 14:31-40.
43. Groen, J., J. Dalrymple, S. Fisher-Hoch, et al. 1992. Serum antibodies to structural proteins of hantavirus arise at different times after infection. J. Med. Virol. 37:283-287.
44. Groen, J., M. Gerding, J.G.M. Jordans, et al. 1994. Class and subclass distribution of hantavirus-specific serum antibodies at different times after the onset of nephropathia epidemica. J. Med. Virol. 43:39-43.
45. Gupta, R.K., C.N. Misra, V.K. Gupta, et al. 1991. An efficient method for production of purified inactivated Japanese encephalitis vaccine from mouse brains. Vaccine. 9:865-867.
46. Hinrichsen, S., A. Medeiros de Andrade, J. Clement, et al. 1993. Hantavirus infection in Brazilian patients from Recife with suspected leptospirosis. Lancet. 2:341:50.
47. Hjelle, B., S. Jenison, N. Torrez-Martinez, et al. 1994. A novel hantavirus associated with an outbreak of fatal respiratory disease in the southwestern United States: evolutionary relationships to known hantaviruses. J. Virol. 68:592-596.
48. Hjelle, B. 2002. Vaccines against hantaviruses. Expert. Rev. Vaccines. 1:373-384.
49. Hooper, J.W., K.I. Kamrud, F. Elgh, et al. 1999. DNA vaccination with hantavirus M segments elicits neutralizing antibodies and protects against Seoul virus infection. Virology. 255:269-278.
50. Hooper, J.W., D. Li. 2001. Vaccines against hantaviruses. Curr. Top. Microbiol. Immunol. 256:171-191.
51. Hooper, J.W., D.M. Custer, E. Thompson, et al. 2001. DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J. Virol. 75:8469-8477.
52. Hörling, J., A. Lundkvist, J.W. Huggins, et al. 1992. Antibodies to Puumala virus in humans determined by neutralization assay. J. Virol. Methods. 39:139-146.
53. Hörling, J., A. Lundkvist, K. Persson, et al. 1995. Detection and subsequent sequencing of Puumala virus from human specimens by PCR. J. Clin. Microbiol. 33:277-282.
54. Huggins, J.W., G.R. Kim, O.M. Brand, et al. 1986. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 153:489-497.
55. Huggins, J.W., C.M. Hsiang, T.M. Cosgriff, et al. 1991. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164:1119-1127.
56. Hujakka, H., V. Koistinen, I. Kuronen, et al. 2003. Diagnostic rapid tests for acute hantavirus infections: specific tests for Hantaan, Dobrava and Puumala viruses versus a hantavirus combination test. J. Virol. Methods. 108:117-122.
57. Jenison, S., T. Yamada, C. Morris, et al. 1994. Characterization of human antibody responses to four corners hantavirus infections among patients with hantavirus pulmonary syndrome. J. Virol. 68:3000-3006.
58. Johnson, K.M. 2001. Hantaviruses: history and overview. Curr. Top. Microbiol. Immunol. 256:1-14.
59. Kallio-Kokko, H., O. Vapalahti, A. Lundkvist, et al. 1998. Evaluation of Puumala virus IgG and IgM enzyme immunoassays based on recombinant Baculovirus-expressed nucleocapsid protein for early nephropathia epidemica diagnosis. Clin. Diagn. Virol. 10:83-90.
60. Kallio-Kokko, H., A. Lundkvist, A. Plyusnin, et al. 2000. Antigenic properties and diagnostic potential of recombinant Dobrava virus nucleocapsid protein. J. Med. Virol. 61:266-274.
61. Kamrud, K.I., J.W. Hooper, F. Elgh, et al. 1999. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters. Virology. 263:209-219.
62. Kanerva, M., K. Melen, A. Vaheri, et al. 1996. Inhibition of Puumala and Tula hantaviruses in Vero cells by MxA protein. Virology. 1:55-62.
63. Kanerva, M., A. Vaheri, J. Mustonen, et al. 1998. High-producer allele of tumour necrosis factor-alpha is part of the susceptibility MHC haplotype in severe Puumala-virus-induced nephropathia epidemica. Scan. J. Infect. Dis. 30:532-534.
64. Kanerva, M., J. Mustonen, A. Vaheri. 1998. Pathogenesis of Puumala and other hantavirus infections. Rev. Med. Virol. 8:67-86.
65. Keyaerts, E., E. Ghijsels, P. Lemey, et al. 2004. Plasma exchange-associated immunoglobulin M-negative hantavirus disease after a camping holiday in Southern France. Clin. Infect. Dis. 38:1350-1356.
66. Khaiboullina, S.F., D.M. Netski, P. Krumpe, et al. 2000. Effects of tumor necrosis factor alpha on Sin Nombre virus infection in vitro. J. Virol. 74:11966-11971.
67. Khaiboullina, S.F., S.C. St. Jeor. 2002. Hantavirus Immunology. Viral Immunol. 15:609-625.
68. Khattak, S., G. Darai, S. Süle, et al. 2002. Characterization of expression of Puumala virus nucleocapsid protein in transgenic plants. Intervirology. 45:334-339.
69. + T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J. Immunol. 172:3297-3304.
70. Kim, S.J., H.W. Sung, J.H. Han, et al. 2004. Protection against very virulent infectious bursal disease virus in chickens immunized with DNA vaccines. Vet. Microbiol. 101:39-51.
71. Klempa, B., H. Meisel, S. Rath, et al. 2003. Occurrence of renal and pulmonary syndrome in a region of northeast Germany where Tula hantavirus circulates. J. Clin. Microbiol. 41:4894-4897.
72. Klempa, B., H.A. Schmidt, R. Ulrich, et al. 2003. Genetic interaction between distinct Dobrava hantavirus subtypes in Apodemus agrarius and A. flavicollis in nature. J. Virol. 77:804-809.
73. Klempa, B., M. Schütt, B. Auste, et al. 2004. First molecular identification of human Dobrava virus infection in Central Europe. J. Clin. Microbiol. 42:1322-1325.
74. Klingström, J., A. Plyusnin, A. Vaheri, et al. 2002. Wild-type Puumala hantavirus infection induces cytokines C-reactive protein, creatinine, and nitric oxide in Cynomolgus macaques. J. Virol. 76:444-449.
75. Koletzki, D., A. Lundkvist, K. Brus Sjölander, et al. 2000. Puumala (PUU) hantavirus strain differences and insertion positions in the Hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. Virology. 276:364-375.
76. Koletzki, D., R. Schirmbeck, A. Lundkvist, et al. 2001. DNA vaccination of mice with a plasmid encoding Puumala hantavirus nucleocapsid protein mimics the B-cell response induced by virus infection. J. Biotechnol. 84:73-78.
77. Koraka, P., B. Murgue, X. Deparis, et al. 2003. Elevated levels of total and dengue virus-specific immunoglobulin E in patients with varying disease severity. J. Med. Virol. 70:91-98.
78. Kraus, A.A., M.J. Raftery, T. Giese, et al. 2004. Differential antiviral response of endothelial cells after infection with pathogenic and nonpathogenic hantaviruses. J. Virol. 78:6143-6150.
79. Lahdevirta, J. 1971. Nephropathia epidemica in Finland. A clinical histological and epidemiological study. Ann. Clin. Res. 3:1-54.
80. Lednicky, J.A. 2003. Hantaviruses. Arch. Pathol. Lab. Med. 127:30-35.
81. LeDuc, J.W., G.A. Smith, K.M. Johnson. 1984. Hantaan-like viruses from domestic rats captured in the United States. Am. J. Trop. Med. Hyg. 33:992-998.
82. Lee, H.W., P.W. Lee, K.M. Johnson. 1978. Isolation of the etiologic agent of Korean hemorrhagic fever. J. Infect Dis. 137:298-308.
83. Lee, H.W., H.J. Cho. 1981. Electron microscope appearance of Hantaan virus, the causative agent of Korean haemorrhagic fever. Lancet. 1:1070-1072.
84. Lee, K.Y., E. Chun, N.Y. Kim, et al. 2002. Characterization of HLA-A2.1-restricted epitopes, conserved in both Hantaan and Sin Nombre viruses, in Hantaan virus-infected patients. J. Gen. Virol. 83:1131-1136.
85. Lewis, R.M., H.W. Lee, A.F. See, et al. 1991. Changes in populations of immune effector cells during the course of haemorrhagic fever with renal syndrome. Trans. R. Soc. Trop. Med. Hyg. 85:282-286.
86. Li, Z., X. Bia, H. Bian. 2002. Serologic diagnosis of Hantaan virus infection based on a peptide antigen. Clin. Chem. 48:645-647.
87. Liang, M., M. Mahler, J. Koch, et al. 2003. Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. J. Med. Virol. 69:99-107.
88. Linderholm, M., L. Bjermer, P. Juto, et al. 1993. Local host response in the lower respiratory tract in nephropathia epidemica. Scan. J. Infect. Dis. 25:639-646.
89. Linderholm, M., C. Ahlm, B. Settergren, et al. 1996. Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J. Infect. Dis. 173:38-43.
90. Linderholm, M., F. Elgh. 2001. Clinical characteristics of hantavirus infections on the Eurasian continent. Curr. Top. Microbiol. Immunol. 256:135-151.
91. Lodmell, D.L., M.J. Parnell, J.T. Weyhrich, et al. 2003. Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody. Vaccine. 21:3998-4002.
92. Lokugamage, K., H. Kariwa, N. Lokugamage, et al. 2004. Genetic and antigenic characterization of the Amur virus associated with hemorrhagic fever with renal syndrome. Virus Res. 101:127-134.
93. Lu, Q., Z. Zhu, J. Weng. 1996. Immune response to inactivated vaccine in people naturally infected with hantaviruses. J. Med. Virol. 1996. 49:333-335.
94. Lundkvist, A., B. Niklasson. 1992. Bank vole monoclonal antibodies against Puumala virus envelope glycoproteins: identification of epitopes involved in neutralization. Arch. Virol. 126:93-105.
95. Lundkvist, A., J. Hörling, B. Niklasson. 1993. The humoral response to Puumala virus infection (nephropathia epidemica) investigated by viral protein specific immunoassays. Arch. Virol. 130:121-130.
96. Lundkvist, A., S. Björsten, B. Niklasson. 1993. Immunoglobulin G subclass responses against the structural components of Puumala virus. J. Clin. Microbiol. 31:368-372.
97. Lundkvist, A., B. Niklasson. 1994. Hemorrhagic fever with renal syndrome and other hantavirus infections. Rev. Med. Virol. 4:177-184.
98. Lundkvist, A., O. Vapalahti, A. Plyusnin, et al. 1996. Characterization of Tula virus antigenic determinants defined by monoclonal antibodies raised against baculovirus-expressed nucleocapsid protein. Virus Res. 45:29-44.
99. Lundkvist, A., H. Kallio-Kokko, K. Bros-Sjölander, et al. 1996. Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. Virology. 216:397-406.
100. Lundkvist, A., M. Hukic, J. Horling, et al. 1997. Puumala and Dobrava viruses cause hemorrhagic fever with renal syndrome in Bosnia-Herzegovina: evidence of highly cross-neutralizing antibody responses in early patient sera. J. Med. Virol. 53:51-59.
101. Lundkvist, A., H. Meisel, D. Koletzki, et al. 2002. Mapping of B-cell epitopes in the nucleocapsid protein of Puumala hantavirus. Viral Immunol. 15:177-192.
102. Mackow, E.R., I.N. Gavrilovskaya. 2001. Cellular receptors and hantavirus pathogenesis. Curr. Top. Microbiol. Immunol. 256:91-116.
103. Maes, P., E. Keyaerts, J. Clement, et al. 2004. Detection of Puumala hantavirus antibody with ELISA using a recombinant truncated nucleocapsid protein expressed in Escherichia coli. Viral Immunol. 17:315-321.
104. Makela, S., J. Mustonen, I. Ala-Houhala, et al. 2002. Human leukocytes antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-α(-308) G/A polymorphism. J. Infect. Dis. 186:843-846.
105. Makela, S., J. Mustonen, I. Ala-Houhala, et al. 2004. Urinary excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced nephritis. Am. J. Kidney Dis. 43:809-816.
106. Markotic, A., G. Dasic, A. Gagro, et al. 1999. Role of peripheral blood mononuclear cell (PBMC) phenotype changes in the pathogenesis of haemorrhagic fever with renal syndrome (HFRS). Clin. Exp. Immunol. 115:329-334.
107. Markotic, A., A. Gagro, G. Dasic, et al. 2002. Immune parameters in hemorrhagic fever with renal syndrome during the incubation and acute disease: case report. Croat. Med. J. 43:587-590.
108. McClain, D.J., P.L. Summers, S.A. Harrison, et al. 2000. Clinical evaluation of a vaccinia vectored Hantaan virus vaccine. J. Med. Virol. 60:77-85.
109. Merten, O.W., C. Hannoun, J.C. Manuguerra, et al. 1996. Production of influenza virus in cell culture for vaccine preparation. Adv. Exp. Med. Biol. 397:141-151.
110. Montagnon, B.J., B. Fanget, A.J. Nicolas. 1981. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. 47:55-64.
111. Mori, M., A.L. Rothman, I. Kurane, et al. 1999. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J. Infect. Dis. 179:295-302.
112. Mustonen, J., J. Partanen, M. Kanerva, et al. 1996. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney Int. 49:217-221.
113. Nichol, S.T., C.F. Spiropoulou, S. Morzunov, et al. 1993. Genetic identification of a novel hantavirus associated with an outbreak of acute respiratory illness in the southwestern United States. Science. 262:914-917.
114. Niikura, M., A. Maeda, T. Ikegami, et al. 2004. Modification of endothelial cell functions by Hantaan virus infection: prolonged hyper-permeability induced by TNF-alpha of Hantaan virus-infected endothelial cell monolayers. Arch. Virol. 149:1279-1292.
115. Nolte, K.B., R.M. Feddersen, K. Foucar, et al. 1995. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum. Pathol. 26:110-120.
116. Padula, P.J., A. Edelstein, S. Miguel, et al. 1998. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology. 241:323-330.
117. Padula, P.J., C.M. Rossi, M.O. Della Valle, et al. 2000. Development and evaluation of a solid-phase enzyme immunoassay based on Andes hantavirus recombinant nucleoprotein. Med. Microbiol. 49:149-155.
118. Padula, P.J., S.B. Colavecchia, V.P. Martinez, et al. 2000. Genetic diversity, distribution, and serological features of hantavirus infection in five countries in South America. J. Clin. Microbiol. 38:3029-3035.
119. Park, C.W., S.N. Yun, C.W. Yang, et al. 1997. Serum and urine soluble HLA class I antigen concentrations are increased in patients with hemorrhagic fever with renal syndrome. Korean J. Intern. Med. 12:52-57.
120. Pellegrino, M.G., M.H. Bluth, T. Smith-Norowitz, et al. 2002. HIV type 1-specific IgE in serum of long-term surviving children inhibits HIV type 1 production in vitro. AIDS Res. Hum. Retroviruses. 18:363-372.
121. Pensiero, M.N., J.B. Sharefkin, C.W. Dieffenbach, et al. 1992. Hantaan virus infection of human endothelial cells. J. Virol. 66:5929-5936.
122. Peters, C.J., A.S. Khan. 2002. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin. Infect. Dis. 34:1224-1231.
123. Phillips, D., I. Charo, L. Parise. 1988. The platelet membrane glycoproteins GPIIb/IIIa complex. Blood. 71:831-843.
124. Plyusnin, A., O. Vapalahti, A. Vaheri. 1996. Hantaviruses: genome structure, expression and evolution. J. Gen. Virol. 77:2677-2687.
125. Plyusnin, A., J. Horling, M. Kanerva, et al. 1997. Puumala hantavirus genome in patients with nephropathia epidemica: correlation of PCR positivity with HLA haplotype and link to viral sequences in local rodents. J. Clin. Microbiol. 35:1090-1096.
126. Plyusnin, A., D.H. Krüger, A. Lundkvist. 2001. Hantavirus infections in Europe. Adv Virus Res. 57:105-136.
127. Pumpens, P., E. Gens. 2001. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology. 44:98-114.
128. Raftery, M.J., A.A. Kraus, R. Ulrich, et al. 2002. Hantavirus infection of dendritic cells. J. Virol. 76:10724-10733.
129. Rizvanov, A.A., A.G.M. van Geelen, S. Morzunov, et al. 2003. Generation of a recombinant Cytomegalovirus for expression of a hantavirus glycoproteins. J. Virol. 77:12203-12210.
130. Romagnani, S. 1992. Human Th1 and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int. Arch. Allergy Immunol. 98:279-285.
131. Schmaljohn, C.S., J.M. Dalrymple. 1983. Analysis of Hantaan virus RNA: evidence of a new genus Bunyaviridae. Virology. 131:482-491.
132. Schmaljohn, C.S., Y.K. Chu, A.L. Schmaljohn, et al. 1990. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J. Virol. 64:3162-3170.
133. Schmaljohn, C.S., S.E. Hasty, J.M. Dalrymple. 1992. Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome. Vaccine. 10:10-13.
134. Severson, W.E., C.S. Schmaljohn, A. Javadian, et al. 2003. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77:481-488.
135. Sirola, H., E.R. Kallio, V. Koistinen, et al. 2004. Rapid field test for detection of hantavirus antibodies in rodents. Epidemiol. Infect. 132:549-553.
136. Sjölander, K.B., F. Elgh, H. Kallio-Kokko, et al. 1997. Evaluation of serological methods for diagnosis of Puumala hantavirus infection (nephropathia epidemica). J. Clin. Microbiol. 35:3264-3268.
137. Sjölander, K.B., A. Lundkvist. 1999. Dobrava virus infection: serological diagnosis and cross-reactions to other hantaviruses. J. Virol. Methods. 80:137-143.
138. Smadel, J.E. 1953. Epidemic hemorrhagic fever. Am. J. Public Health. 43:1327-1330.
139. Smee, D.F., R.W. Sidwell, J.H. Huffman, et al. 1996. Antiviral activities of Tragacanthin polysaccharides on Punta Toro virus infections in mice. Chemotherapy. 42:286-293.
140. Sohn, Y.M., H.O. Rho, M.S. Park, et al. 2001. Primary humoral immuno responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea. Yonsei Med. J. 42:278-284.
141. Song, G., Y.C. Huang, C.S. Hang, et al. 1992. Preliminary human trial of inactivated golden hamster kidney cell (GHKC) vaccine against haemorrhagic fever with renal syndrome (HFRS). Vaccine. 10:214-216.
142. Stohwasser, R., K. Raab, G. Darai, et al. 1991. Primary structure of the large (L) RNA segment of nephropathia epidemica virus strain Hällnäs B1 coding for the viral RNA polymerase. Virology. 183:386-391.
143. Sundstrom, J.B., L.K. McMullan, C.F. Spiropoulou, et al. 2001. Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. J. Virol. 75:6070-6085.
144. Tamura, M., H. Asada, K. Kondo, et al. 1987. Effects of human and murine interferons against hemorrhagic fever with renal syndrome (HFRS) virus (Hantaan virus). Antiviral Res. 8:171-178.
145. Temonen, M., J. Mustonen, H. Helin, et al. 1996. Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemica kidneys: an immunohistochemical study. Clin. Immunol. Immunopathol. 78:47-55.
146. Teramija, M., J.D. Hendershot, H. Kariwa, et al. 1999. High levels of viremia in patients with the hantavirus pulmonary syndrome. J. Infect. Dis. 180:2030-2034.
147. Teramija, M., H.L. Van Epps, D. Li, et al. 2002. Generation of recombinant vaccinia viruses expressing Puumala virus proteins and use in isolating cytotoxic T cells specific for Puumala virus. Virus Res. 84:67-77.
148. Terajima, M., A. Vapalahfi, H.L. Van Epps, et al. 2004. Immune responses to Puumala virus infection and the pathogenesis of nephropathia epidemica. Microbes Infect. 6:238-245.
149. Tkachenko, E.A., H.W. Lee. 1991. Etiology and Epidemiology of hemorrhagic fever with renal syndrome. Kidney Int. 40 (suppl.35):S54-S61.
150. Tracey, K.J., Y. Fong, D.G. Hesse, et al. 1987. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature. 330:662-664.
151. Ulrich, R., A. Lundkvist, H. Meisel, et al. 1998. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine. 16:272-280.
152. + CTL epitopes on nucleocapsid protein. J. Virol. 73:5301-5308.
153. Van Epps, H.L., M. Terajima, J. Mustonen, et al. 2002. Long-lived memory T lymphocyte responses after hantavirus infection. J. Exp. Med. 196:579-588.
154. Vapalahti, O., H. Kallio-Kokko, A. Närvänen, et al. 1995. Human B-cell epitopes of Puumala virus nucleocapsid protein, the major antigen in early serological response. J. Med. Virol. 46:293-303.
155. Vilcek, J., T.H. Lee. 1991. Tumor necrosis factor. J. Biol. Chem. 266:7313-7316.
156. Xiao, S.Y., R. Yanagihara, M.S. Godec, et al. 1991. Detection of hantavirus RNA in tissues of experimentally infected mice using reverse transcriptase directed polymerase chain reaction. J. Med. Virol. 33:277-282.
157. Xu, X., S.L. Ruo, J.B. McCormick, et al. 1992. Immunity to hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am. J. Trop. Med. Hyg. 47:397-404.
158. Yamanishi, K., O. Tanishita, M. Tamura, et al. 1988. Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome. Vaccine. 6:278-282.
159. Yanagihara, R., D.J. Silverman. 1990. Experimental infection of human vascular endothelial cells by pathogenic and non-pathogenic hantaviruses. Arch. Virol. 111:281-286.
160. Ye, C., J. Prescott, R. Nofchissey, et al. 2004. Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg. Infect. Dis. 10:478-482.
161. Yoshimatsu, K., Y.C. Yoo, R. Yoshida, et al. 1993. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Arch. Virol. 130:365-376.
162. Zaki, S.R., P.W. Greer, L.M. Coffield, et al. 1995. Hantavirus pulmonary syndrome - pathogenesis of an emerging infectious disease. Am. J. Pathol. 146:552-579.
163. Zöller, L., S. Yang, P. Gött, et al. 1993. A novel μ-capture EIA based on recombinant proteins for sensitive and specific diagnosis of hemorrhagic fever with renal syndrome. J. Clin. Microbiol. 31:1194-1199.